SCHEMBL9195477

SCHEMBL9195477

CCOC(=O)Oc1ccc(N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
MAOA P21397 1/20 0.56
KMT2A Q03164 6/20 0.50
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP14 P50281 1/20 0.47
PPIB P23284 1/20 0.46
PPIA P62937 1/20 0.46
PPID Q08752 1/20 0.46
PPIG Q13427 1/20 0.46
PDE4D Q08499 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CA2 P00918 1/20 0.45
ALDH1A1 P00352 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451238 0.90 ALDH1A1 (0.55) LMNAKMT2ATSHRMMP2MMP9
SCHEMBL1598705 0.84 LMNA (0.57) LMNAKMT2AMMP2MMP9MMP8
SCHEMBL8536318 0.82 CA2 (0.55) LMNACYP1A2KMT2ATSHRTDP1
SCHEMBL6894576 0.82 GAA (0.51) LMNAKMT2ATSHRMMP2MMP9
SCHEMBL8983166 0.81 SMN1; SMN2 (0.51) LMNAKMT2ATDP1MMP2MMP9
SCHEMBL2132487 0.81 TDP1 (0.50) CYP3A4MAOAKMT2ATSHRTDP1
SCHEMBL23758132 0.81 TDP1 (0.41) LMNACYP1A2CYP3A4MAOAKMT2A
SCHEMBL11597793 0.81 KMT2A (0.50) LMNAKMT2ATSHRMMP2MMP9
SCHEMBL1788818 0.81 KMT2A (0.49) LMNACYP1A2KMT2ATDP1MMP2
SCHEMBL24418978 0.81 KMT2A (0.49) LMNAKMT2AMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2023-02-16 US disclosed
EP-0482508-B1 Biscationic azo dyes and their intermediates BASF AG (DE) 1995-07-12 EP disclosed
EP-0482508-A1 Biscationic azo dyes and their intermediates BASF Aktiengesellschaft (DE) 1992-04-29 EP disclosed
US-4942242-A ANTICHOLESTEROL AGENTS KOJIMA TADAO (JP) 1990-07-17 US disclosed
US-4798838-A ANTICOAGULANTS, ANTICHOLESTEROL AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1989-01-17 US disclosed
US-4795753-A Certain pyridyl or imidazol-1-yl-alkyleneoxy-(or amino)phenoxy-alkanoates having lipid lowering activity YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1989-01-03 US disclosed
US-4794113-A ANTICHOLESTEROL, ANTILIPEMIC, ANTICOAGULANT YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1988-12-27 US disclosed
EP-0130077-A2 Phenoxy derivatives, their preparation, and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1985-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 LMNA 3441/4885CYP1A2 4081/4885CYP3A4 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.